Sort
51,593 grants matching “hepatitis”
DETECTION AND MODELS OF TOXICANT EXPOSURE
$2,379,199Robert H Tukey · University Of California, San Diego · P42 · FY2017 · ES
AIDS Linked to the IntraVenous Experience (ALIVE) Study
$2,378,750Shruti H Mehta · Johns Hopkins University · U01 · FY2025 · DA
Emerging Infections Program
$2,378,521Paul R Cieslak · Public Health Services · U01 · FY2008 · CI
Adeno-associated Virus Biology And Utilization For Gene Transfer
$2,377,221John A Chiorini · National Institute Of Dental & Craniofacial Research · ZIA · FY2012 · DE
A vaccine design to induce protective B and T cell immunity against hepatitis C virus
$2,377,023Steven Foung · Stanford University · U19 · FY2021 · AI
The UCSD CD4 Collaborative Clinical Trial Unit
$2,370,023Constance Ann Benson · University Of California, San Diego · UM1 · FY2017 · AI
Real-time prediction of emerging drug use epidemics in the United States
$2,367,000Annick Borquez · University Of California, San Diego · DP2 · FY2019 · DA
The role of stem cells in skeletal health and disease
$2,364,525Pamela G Robey · National Institute Of Dental & Craniofacial Research · ZIA · FY2020 · DE
A major contributor of serious multisystem disease in the elderly: varicella zoster virus-induced inflammation
$2,364,341Maria Acena Nagel · University Of Colorado Denver · P01 · FY2019 · AG
DETECTION AND MODELS OF TOXICANT EXPOSURE
$2,363,608Robert H Tukey · University Of California, San Diego · P42 · FY2020 · ES
Triglycerides, Diabetes and Cardiovascular Disease
$2,360,354Karin E. Bornfeldt · University Of Washington · P01 · FY2022 · HL
LICI Microbiome and Genetics Core
$2,356,885Colm Ohuigin · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Pitt-Ohio State Clinical Trials Unit
$2,355,644John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2022 · AI
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,354,481Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2016 · ES
Synergies among inhibitory receptors in tolerance, cancer & antiviral immunity
$2,353,012Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · P01 · FY2020 · AI
Mechanisms and biological consequences of the nuclear receptor CAR activation
$2,352,234Masahiko Negishi · National Institute Of Environmental Health Sciences · ZIA · FY2013 · ES
Genetics of Brain Development
$2,352,119Maximilian Muenke · National Human Genome Research Institute · ZIA · FY2019 · HG
Reversal of Immune Failure with Viral Cure in Chronic HCV Infection
$2,351,111Raymond T Chung · Massachusetts General Hospital · U19 · FY2014 · AI
Emerging Infections Program
$2,345,768Paul R Cieslak · Public Health Services · U01 · FY2010 · CI
Molecular Biology and Genetics of Human Tumor Viruses
$2,345,231Paul F Lambert · University Of Wisconsin-Madison · P01 · FY2020 · CA
Pitt-Ohio State Clinical Trials Unit
$2,344,903John W Mellors · University Of Pittsburgh At Pittsburgh · UM1 · FY2021 · AI
Triglycerides, Diabetes and Cardiovascular Disease
$2,342,163Karin E. Bornfeldt · University Of Washington · P01 · FY2021 · HL
HIV Neurobehavioral Research Center
$2,341,857Igor Grant · University Of California, San Diego · P30 · FY2010 · MH
Improvements to the Regional Biocontainment Research Facilities at the University of Missouri
$2,340,729Christian L. Lorson · University Of Missouri-Columbia · G20 · FY2022 · AI
Hepatobiology and Toxicology COBRE
$2,340,000Craig J McClain · University Of Louisville · P20 · FY2021 · GM